Role of cholecystokinin in appetite control and body weight regulation

Obesity Reviews

Volumn 6, Issue 4, 2005, Pages 297-306

  Little, T J ^a   Horowitz, M ^a   Feinle Bisset, C ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Cholecystokinin; Energy intake; Obesity

Indexed keywords

1,5 BENZODIAZEPINE CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; AR R 14294; AR R 15849; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; GW 181771; UNCLASSIFIED DRUG;

ANATOMY; APPETITE; BILE SECRETION; BODY WEIGHT; CALORIC INTAKE; DIET; HUMAN; INCIDENCE; INTESTINE FUNCTION; OBESITY; PANCREAS SECRETION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN FUNCTION; REVIEW; STIMULUS RESPONSE; STOMACH FUNCTION; WEIGHT REDUCTION;

ANIMALS; APPETITE; BODY WEIGHT; CHOLECYSTOKININ; DIGESTIVE PHYSIOLOGY; ENERGY INTAKE; GASTROINTESTINAL HORMONES; HORMONE ANTAGONISTS; HUMANS; OBESITY; PROGLUMIDE; RECEPTORS, CHOLECYSTOKININ;

EID: 27644577645     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2005.00212.x     Document Type: Review

References (101)

1. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643.
2. Chen D, Zhao CM, Hakanson R, Samuelson LC, Rehfeld JF, Friis-Hansen L. Altered control of gastric acid secretion in gastrincholecystokinin double mutant mice. Gastroenterology 2004; 126: 476-487.
3. Ivy AC, Oldberg E. Contraction and evacuation of gallbladder by a purified 'secretin' preparation. J Am Med Assoc 1928; 90: 445-446.
4. Harper AA, Raper HS. Pancreozymin, a stimulant for secretion of pancreatic enzymes in extracts of the small intestine. J Physiol 1943; 102: 115-125.
5. Liddle RA, Gertz BJ, Kanayama S, Beccaria L, Coker LD, Turnbull TA, Morita ET. Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. J Clin Invest 1989; 84: 1220-1225.
6. Valenzuela JE, Defilippi C. Inhibition of gastric emptying in humans by secretion, the octapeptide of cholecystokinin, and intraduodenal fat. Gastroenterology 1981; 81: 898-902.
7. Fraser R, Fone D, Horowitz M, Dent J. Cholecystokinin octapeptide stimulates phasic and tonic pyloric motility in healthy humans. Gut 1993; 34: 33-37.
8. Brennan IM, Feltrin KL, Horowitz M, Smout AJ, Meyer JH, Wishart J, Feinle-Bisset C. Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake and antropyloroduodenal motility in healthy men. Am J Physiol Regul Integr Comp Physiol 2005; 288: 477-485.
9. Muurahainen N, Kissileff HR, Derogatis AJ, Pi-Sunyer FX. Effects of cholecystokinin-octapeptide (CCK-8) on food intake and gastric emptying in man. Physiol Behav 1988; 44: 645-649.
10. Beglinger C, Degen L, Matzinger D, D'Amato M, Drewe J. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am J Physiol Regul Integr Comp Physiol 2001; 280: 1149-1154.
11. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 1981; 34: 154-160.
12. MacIntosh CG, Morley JE, Wishart J, Morris H, Jansen JB, Horowitz M, Chapman IM. Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: evidence for increased CCK activity as a cause of the anorexia of aging. J Clin Endocrinol Metab 2001; 86: 5830-5837.
13. Phillipp E, Pirke KM, Kellner MB, Krieg JC. Disturbed cholecystokinin secretion in patients with eating disorders. Life Sci 1991; 48: 2443-2450.
14. Geracioti TD Jr, Kling MA, Joseph-Vanderpool JR, Kanayama S, Rosenthal NE, Gold PW, Liddle RA. Meal-related cholecystokinin secretion in eating and affective disorders. Psychopharmacol Bull 1989; 25: 444-449.
15. Rehfeld JF. Four basic characteristics of the gastrin-cholecystokinin system. Am J Physiol Gastrointest Liver Physiol 1981; 240: 255-266.
16. Eberlein GA, Eysselein VE, Davis MT, Lee TD, Shively JE, Grandt D, Niebel W, Williams R, Moessner J, Zeeh J, et al. Patterns of prohormone processing. Order revealed by a new procholecystokinin-derived peptide. J Biol Chem 1992; 267: 1517-1521.
17. Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clin Chem 1998; 44: 991-1001.
18. Eberlein GA, Eysselein VE, Goebell H. Cholecystokinin-58 is the major molecular form in man, dog and cat but not in pig, beef and rat intestine. Peptides 1988; 9: 993-998.
19. Rehfeld JF, Sun G, Christensen T, Hillingso JG. The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33. J Clin Endocrinol Metab 2001; 86: 251-258.
20. Miyasaka K, Guan DF, Liddle RA, Green GM. Feedback regulation by trypsin: evidence for intraluminal CCK-releasing peptide. Am J Physiol Gastrointest Liver Physiol 1989; 257: 175-181.
21. Spannagel AW, Reeve JR Jr, Greeley GH Jr, Yanaihara N, Liddle RA, Green GM. Bioactivity of intraduodenally and intravenously infused fragments of luminal cholecystokinin releasing factor (LCRF). Regul Pept 1998; 73: 161-164.
22. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 1985; 75: 1144-1152.
23. Larsson LI, Rehfeld JF. Distribution of gastrin and CCK cells in the rat gastrointestinal tract. Evidence for the occurrence of three distinct cell types storing COOH-terminal gastrin immunoreactivity. Histochemistry 1978; 58: 23-31.
24. Lieverse RJ, Jansen JB, Masclee AA, Rovati LC, Lamers CB. Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide. Gut 1994; 35: 501-505.
25. Parker B, Doran S, Wishart J, Horowitz M, Chapman IM. Effects of small intestinal and gastric glucose administration on the suppression of plasma ghrelin concentrations in healthy older men and women. Clin Endocrinol (Oxf) 2005; 62: 539-546.
26. Larsson LI, Rehfeld JF. Localization and molecular heterogeneity of cholecystokinin in the central and peripheral nervous system. Brain Res 1979; 165: 201-218.
27. Rehfeld JF. Immunochemical studies on cholecystokinin. II. Distribution and molecular heterogeneity in the central nervous system and small intestine of man and hog. J Biol Chem 1978; 253: 4022-4030.
28. Moran TH, Kinzig KP. Gastrointestinal satiety signals II. Cholecystokinin. Am J Physiol Gastrointest Liver Physiol 2004; 286: 183-188.
29. Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides 1994; 15: 731-755.
30. Moran TH, Robinson PH, Goldrich MS, McHugh PR. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 1986; 362: 175-179.
31. Wank SA, Harkins R, Jensen RT, Shapira H, de Weerth A, Slattery T. Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc Natl Acad Sci USA 1992; 89: 3125-3129.
32. Smith GT, Moran TH, Coyle JT, Kuhar MJ, O'Donahue TL, McHugh PR. Anatomic localization of cholecystokinin receptors to the pyloric sphincter. Am J Physiol Regul Integr Comp Physiol 1984; 264: 127-130.
33. Hill DR, Campbell NJ, Shaw TM, Woodruff GN. Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J Neurosci 1987; 7: 2967-2976.
34. Pandya PK, Huang SC, Talkad VD, Wank SA, Gardner JD. Biochemical regulation of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini. Biochim Biophys Acta 1994; 1224: 117-126.
35. Weatherford SC, Laughton WB, Salabarria J, Danho W, Tilley JW, Neterville LA, Schwartz GJ, Moran TH. CCK satiety is differentially mediated by high- and low-affinity CCK receptors in mice and rats. Am J Physiol Regul Integr Comp Physiol 1993; 264: 244-249.
36. Wank SA, Pisegna JR, de Weerth A. Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human. Ann N Y Acad Sci 1994; 713: 49-66.
37. Gaudreau P, Quirion R, St-Pierre S, Pert CB. Characterization and visualization of cholecystokinin receptors in rat brain using [3H]pentagastrin. Peptides 1983; 4: 755-762.
38. Baldwin BA, Parrott RF, Ebenezer I. Food for thought: a critique on the hypothesis that endogenous cholecystokinin acts as a physiological satiety factor. Prog Neurobiol 1998; 55: 477-507.
39. Liddle RA, Morita ET, Conrad CK, Williams JA. Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest 1986; 77: 992-996.
40. Meyer BM, Werth BA, Beglinger C, Hildebrand P, Jansen JB, Zach D, Rovati LC, Stalder GA. Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet 1989; 2: 12-15.
41. Ivy AC, Oldberg E. Contraction and evacuation of gall-bladder caused by highly purified 'secretin' preparation. Proc Soc Exp Biol Medical 1927; 25: 113-115.
42. Jorpes E, Mutt V. Cholecystokinin and pancreozymin, one single hormone? Acta Physiol Scand 1966; 66: 196-202.
43. Fried M, Erlacher U, Schwizer W, Lochner C, Koerfer J, Beglinger C, Jansen JB, Lamers CB, Harder F, Bischof-Delaloye A, Stalder GA, Rovati L. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology 1991; 101: 503-511.
44. Yamagishi T, Debas HT. Cholecystokinin inhibits gastric emptying by acting on both proximal stomach and pylorus. Am J Physiol Endocrinol Metab 1978; 234: 375-378.
45. Ludtke FE, Golenhofen K, Kohne C. Direct effects of cholecystokinin on human gastric motility. Digestion 1988; 39: 210-218.
46. Fraser RFD, Horowitz M, Dent J. Cholecystokinin octapeptide stimulates phasic and tonic pyloric motility in healthy humans. Gut 1993; 34: 33-37.
47. Rayner CK, Park HS, Doran SM, Chapman IM, Horowitz M. Effects of cholecystokinin on appetite and pyloric motility during physiological hyperglycemia. Am J Physiol Gastrointest Liver Physiol 2000; 278: 98-104.
48. Kellow JE, Miller LJ, Phillips SF, Haddad AC, Zinsmeister AR, Charboneau JW. Sensitivities of human jejunum, ileum, proximal colon, and gallbladder to cholecystokinin octapeptide. Am J Physiol Gastrointest Liver Physiol 1987; 252: 345-356.
49. Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 1973; 84: 488-495.
50. Antin J, Gibbs J, Holt J, Young RC, Smith GP. Cholecystokinin elicits the complete behavioral sequence of satiety in rats. J Comp Physiol Psychol 1975; 89: 784-790.
51. Gibbs J, Young RC, Smith GP. Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature 1973; 245: 323-325.
52. Lieverse RJ, Jansen JB, Masclee AM, Lamers CB. Satiety effects of cholecystokinin in humans. Gastroenterology 1994; 106: 1451-1454.
53. Ballinger A, McLoughlin L, Medbak S, Clark M. Cholecystokinin is a satiety hormone in humans at physiological postprandial plasma concentrations. Clin Sci (Lond) 1995; 89: 375-381.
54. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Satiety effects of a physiological dose of cholecystokinin in humans. Gut 1995; 36: 176-179.
55. Blundell JE, Hill AJ, Rogers PJ. Hunger and the satiety cascade - their importance for food acceptance in the late 20th century. In: Dmh T (ed.). Food Acceptability. Elsevier, Amsterdam, 1988, pp. 233-250.
56. West DB, Greenwood MR, Sullivan AC, Prescod L, Marzullo LR, Triscari J. Infusion of cholecystokinin between meals into free-feeding rats fails to prolong the intermeal interval. Physiol Behav 1987; 39: 111-115.
57. Muurahainen NE, Kissileff HR, Lachaussee J, Pi-Sunyer FX. Effect of a soup preload on reduction of food intake by cholecystokinin in humans. Am J Physiol Regul Integr Comp Physiol 1991; 260: 672-680.
58. Kissileff HR, Carretta JC, Geliebter A, Pi-Sunyer FX. Cholecystokinin and stomach distension combine to reduce food intake in humans. Am J Physiol Regul Integr Comp Physiol 2003; 285: 992-998.
59. Feinle C, Chapman IM, Wishart J, Horowitz M. Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in healthy and obese men. Peptides 2002; 23: 1491-1495.
60. Onaga T, Zabielski R, Kato S. Multiple regulation of peptide YY secretion in the digestive tract. Peptides 2002; 23: 279-290.
61. Lin HC, Chey WY. Cholecystokinin and peptide YY are released by fat in either proximal or distal small intestine in dogs. Regul Pept 2003; 114: 131-135.
62. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117-126.
63. Lavin JH, Wittert G, Sun WM, Horowitz M, Morley JE, Read NW. Appetite regulation by carbohydrate: role of blood glucose and gastrointestinal hormones. Am J Physiol Endocrinol Metab 1996; 271: 209-214.
64. Overduin J, Frayo RS, Grill HJ, Kaplan JM, Cummings DE. Role of the duodenum and macronutrient type in ghrelin regulation. Endocrinology 2005; 146: 845-850.
65. Matson CA, Reid DF, Cannon TA, Ritter RC. Cholecystokinin and leptin act synergistically to reduce body weight. Am J Physiol Regul Integr Comp Physiol 2000; 278: 882-890.
66. Riedy CA, Chavez M, Figlewicz DP, Woods SC. Central insulin enhances sensitivity to cholecystokinin. Physiol Behav 1995; 58: 755-760.
67. Bhavsar S, Watkins J, Young A. Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav 1998; 64: 557-561.
68. Lin HC, Chey WY, Zhao X. Release of distal gut peptide YY (PYY) by fat in proximal gut depends on CCK. Peptides 2000; 21: 1561-1563.
69. Matson CA, Reid DF, Ritter RC. Daily CCK injection enhances reduction of body weight by chronic intracerebroventricular leptin infusion. Am J Physiol Regul Integr Comp Physiol 2002; 282: 1368-1373.
70. Greenough A, Cole G, Lewis J, Lockton A, Blundell J. Untangling the effects of hunger, anxiety, and nausea on energy intake during intravenous cholecystokinin octapeptide (CCK-8) infusion. Physiol Behav 1998; 65: 303-310.
71. Miaskiewicz SL, Stricker EM, Verbalis JG. Neurohypophyseal secretion in response to cholecystokinin but not meal-induced gastric distention in humans. J Clin Endocrinol Metab 1989; 68: 837-843.
72. Matzinger D, Degen L, Drewe J, Meuli J, Duebendorfer R, Ruckstuhl N, D'Amato M, Rovati L, Beglinger C. The role of long chain fatty acids in regulating food intake and cholecystokinin release in humans. Gut 2000; 46: 688-693.
73. Matzinger D, Gutzwiller JP, Drewe J, Orban A, Engel R, D'Amato M, Rovati L, Beglinger C. Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans. Am J Physiol Regul Integr Comp Physiol 1999; 277: 1718-1724.
74. Lieverse RJ, Masclee AA, Jansen JB, Rovati LC, Lamers CB. Satiety effects of the type A CCK receptor antagonist loxiglumide in lean and obese women. Biol Psychiatry 1995; 37: 331-335.
75. Crawley JN, Beinfeld MC. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 1983; 302: 703-706.
76. Covasa M, Marcuson JK, Ritter RC. Diminished satiation in rats exposed to elevated levels of endogenous or exogenous cholecystokinin. Am J Physiol Regul Integr Comp Physiol 2001; 280: 331-337.
77. Lukaszewski L, Praissman M. Effect of continuous infusions of CCK-8 on food intake and body and pancreatic weights in rats. Am J Physiol Regul Integr Comp Physiol 1988; 254: 17-22.
78. Funakoshi A, Miyasaka K, Shinozaki H, Masuda M, Kawanami T, Takata Y, Kono A. An animal model of congenital defect of gene expression of cholecystokinin (CCK)-A receptor. Biochem Biophys Res Commun 1995; 210: 787-796.
79. Moran TH, Katz LF, Plata-Salaman CR, Schwartz GJ. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am J Physiol Regul Integr Comp Physiol 1998; 274: 618-625.
80. Kopin AS, Mathes WF, McBride EW, Nguyen M, Al-Haider W, Schmitz F, Bonner-Weir S, Kanarek R, Beinborn M. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest 1999; 103: 383-391.
81. Funakoshi A, Miyasaka K, Matsumoto H, Yamamori S, Takiguchi S, Kataoka K, Takata Y, Matsusue K, Kono A, Shimokata H. Gene structure of human cholecystokinin (CCK) type-A receptor: body fat content is related to CCK type-A receptor gene promoter polymorphism. FEBS Lett 2000; 466: 264-266.
82. Miller LJ, Holicky EL, Ulrich CD, Wieben ED. Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. Gastroenterology 1995; 109: 1375-1380.
83. Inoue H, Iannotti CA, Welling CM, Veile R, Donis-Keller H, Permutt MA. Human cholecystokinin type A receptor gene: cytogenetic localization, physical mapping, and identification of two missense variants in patients with obesity and non-insulin-dependent diabetes mellitus (NIDDM). Genomics 1997; 42: 331-335.
84. Baranowska B, Radzikowska M, Wasilewska-Dziubinska E, Roguski K, Borowiec M. Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Diabetes Obes Metab 2000; 2: 99-103.
85. Sturm K, MacIntosh CG, Parker BA, Wishart J, Horowitz M, Chapman IM. Appetite, food intake and plasma concentrations of cholecystokinin, ghrelin and other gastrointestinal hormones in under-nourished older women and well-nourished young and older women. J Clin Endocrinol Metab 2003; 88: 3747-3755.
86. French SJ, Murray B, Rumsey RD, Sepple CP, Read NW. Preliminary studies on the gastrointestinal responses to fatty meals in obese people. Int J Obes Relat Metab Disord 1993; 17: 295-300.
87. Voits M, Voigt JP, Boomgaarden M, Henklein P, Fink H. Comparison of the satiating effect of the CCKA receptor agonist A71378 with CCK-8S. Peptides 1996; 17: 355-357.
88. Hirst GC, Aquino C, Birkemo L, Croom DK, Dezube M, Dougherty RW Jr., Ervin GN, Grizzle MK, Henke B, James MK, Johnson MF, Momtahen T, Queen KL, Sherrill RG, Szewczyk J, Willson TM, Sugg EE. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): optimization of the C3 amino substituent. J Med Chem 1996; 39: 5236-5245.
89. Simmons RD, Blosser JC, Rosamond JR. FPL 14294: a novel CCK-8 agonist with potent intranasal anorectic activity in the rat. Pharmacol Biochem Behav 1994; 47: 701-708.
90. Pierson ME, Comstock JM, Simmons RD, Julien R, Kaiser F, Rosamond JD. CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists. J Med Chem 2000; 43: 2350-2355.
91. Pierson ME, Comstock JM, Simmons RD, Kaiser F, Julien R, Zongrone J, Rosamond JD. Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents. J Med Chem 1997; 40: 4302-4307.
92. Simmons RD, Kaiser FC, Hudzik TJ. Behavioral effects of AR-R 15849, a highly selective CCK-A agonist. Pharmacol Biochem Behav 1999; 62: 549-557.
93. Spannagel AW, Nakano I, Tawil T, Chey WY, Liddle RA, Green GM. Adaptation to fat markedly increases pancreatic secretory response to intraduodenal fat in rats. Am J Physiol Gastrointest Liver Physiol 1996; 270: 128-135.
94. Covasa M, Ritter RC. Rats maintained on high-fat diets exhibit reduced satiety in response to CCK and bombesin. Peptides 1998; 19: 1407-1415.
95. French SJ, Murray B, Rumsey RD, Fadzlin R, Read NW. Adaptation to high-fat diets: effects on eating behaviour and plasma cholecystokinin. Br J Nutr 1995; 73: 179-189.
96. Cunningham KM, Daly J, Horowitz M, Read NW. Gastrointestinal adaptation to diets of differing fat composition in human volunteers. Gut 1991; 32: 483-486.
97. Boyd KA, O'Donovan DG, Doran S, Wishart J, Chapman IM, Horowitz M, Feinle C. High-fat diet effects on gut motility, hormone, and appetite responses to duodenal lipid in healthy men. Am J Physiol Gastrointest Liver Physiol 2003; 285: 188-196.
98. Meyer JH, Hlinka M, Tabrizi Y, DiMaso N, Raybould HE. Chemical specificities and intestinal distributions of nutrient-driven satiety. Am J Physiol Regul Integr Comp Physiol 1998; 275: 1293-1307.
99. Rose C, Vargas F, Facchinetti P, Bourgeat P, Bambal RB, Bishop PB, Chan SM, Moore AN, Ganellin CR, Schwartz JC. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature 1996; 380: 403-409.
100. Jack DB. Fighting obesity the Franco-British way. Lancet 1996; 347: 1756.
101. Hill AJ, Peikin SR, Ryan CA, Blundell JE. Oral administration of proteinase inhibitor II from potatoes reduces energy intake in man. Physiol Behav 1990; 48: 241-246.